Advances and Challenges of NanoparticleBased Macrophage Reprogramming for Cancer Immunotherapyстатья

Информация о цитировании статьи получена из Scopus, Web of Science
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 15 августа 2019 г.

Работа с статьей

[1] Advances and challenges of nanoparticlebased macrophage reprogramming for cancer immunotherapy / K. S. Kapitanova, V. A. Naumenko, A. S. Garanina et al. // Biochemistry (Moscow). — 2019. — Vol. 84, no. 7. — P. 729–745. Despite the progress of modern medicine, oncological diseases are still among the most common causes of death of adult populations in developed countries. The current therapeutic approaches are imperfect, and the high mortality of oncological patients under treatment, the lack of personalized strategies, and severe side effects arising as a result of treatment force seeking new approaches to therapy of malignant tumors. During the last decade, cancer immunotherapy, an approach that relies on activation of the host antitumor immune response, has been actively developing. Cancer immunotherapy is the most promising trend in contemporary fundamental and practical oncology, and restoration of the pathologically altered tumor microenvironment is one of its key tasks, in particular, the reprogramming of tumor macrophages from the immunosuppressive M2phenotype into the proinflammatory M1phenotype is pivotal for eliciting antitumor response. This review describes the current knowledge about macrophage classification, mechanisms of their polarization, their role in formation of the tumor icroenvironment, and strategies for changing the functional activity of M2macrophages, as well as problems of targeted delivery of immunostimulatory signals to tumor macrophages using nanoparticles. [ DOI ]

Публикация в формате сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл скрыть